Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

59.17USD
23 May 2018
Change (% chg)

$0.72 (+1.23%)
Prev Close
$58.45
Open
$58.51
Day's High
$59.49
Day's Low
$58.43
Volume
3,376,158
Avg. Vol
3,729,062
52-wk High
$66.41
52-wk Low
$52.83

Select another date:

Wed, May 23 2018

Merck's cancer drug Keytruda notches another trial success

Merck & Co said on Wednesday its drug Keytruda helped patients with a certain type of lung cancer live longer and prevented the disease from spreading, helping to solidify its position in the lucrative cancer market.

UPDATE 2-Merck's cancer drug Keytruda notches another trial success

May 23 Merck & Co said on Wednesday its drug Keytruda helped patients with a certain type of lung cancer live longer and prevented the disease from spreading, helping to solidify its position in the lucrative cancer market.

Merck's Keytruda succeeds late-stage lung cancer study

May 23 Merck & Co on Wednesday said its cancer drug Keytruda had met the main goals of a late-stage study testing it in combination with chemotherapy for a type of lung cancer.

BRIEF-Merck's Keytruda succeeds in squamous non-small cell lung cancer study

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AS FIRST-LINE TREATMENT FOR SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN PIVOTAL PHASE 3 KEYNOTE-407 TRIAL

BRIEF-FDA Issues Alert On Use Of Keytruda/Tecentriq For Patients With Urothelial Cancer, Have Low Expression Of PD-L1

* U.S. FDA - ISSUES ALERT ABOUT DECREASED SURVIVAL ASSOCIATED WITH THE USE OF KEYTRUDA (PEMBROLIZUMAB) OR TECENTRIQ (ATEZOLIZUMAB)

Merck's Keytruda boosts response in hard-to-treat lung cancer

The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday.

Merck's Keytruda boosts response in hard-to-treat lung cancer

May 16 The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday.

BRIEF-Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda

* ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE IL-12 AND KEYTRUDA FOR TRIPLE NEGATIVE BREAST CANCER

BRIEF-Lynparza (Olaparib) Tablets Receive EU Approval For The Treatment Of Platinum-Sensitive Relapsed Ovarian Cancer

* LYNPARZA® (OLAPARIB) TABLETS RECEIVE EU APPROVAL FOR THE TREATMENT OF PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER

BRIEF-Moderna And Merck Expand MRNA Cancer Vaccines Collaboration

* MODERNA AND MERCK EXPAND MRNA CANCER VACCINES COLLABORATION

Select another date: